Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

Axel Grothey, Hans‐Joachim Schmoll, Josep Tabernero et al.|Annals of Oncology|2018

Cited by 103